posted
Bob said i was frontloading,I would not do that, All i wanted to do is let everyone know there was a great pr out and wanted people to realize there was a great one out there to look for! Bob you know me better then that, I already have 25,000 shares, i did tell everyone who asked me what the pick was!!! ok i vented,
OK MCET is the one I think has alot of potential from there pr. I do want to caution folks thats in the last few months they did file form SB4 so dulition is possible today! if you see alot of buying preasure and selling is the same and its not going up, Watch your but, I am playing and gl to all who play!!!!!!!!
MultiCell Technologies Announces Milestone Patent Issued by European Patent Office on Treatments for Autoimmune Diseases
A Newly Granted Patent Covers Company's Immune-Based Therapeutics to Target MS, Diabetes and other Unmet Medical Needs
SAN DIEGO, Oct 12, 2006 (BUSINESS WIRE) -- MultiCell Technologies, Inc. (OTCBB:MCET), developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced that the European Patent Office has granted the Company a key patent covering its next-generation technology targeting multibillion-dollar medical marketplace segments, including a range of serious autoimmune disorders such as diabetes and multiple sclerosis. The patent issuance is a significant validation of the Company's business strategy to obtain broad, worldwide protection of its advanced immune modulation technologies and intellectual property. The Company recently announced that its IP portfolio crossed the key threshold of more than 50 issued or pending patents.
The patent, "Compositions for Treating Autoimmune Disease," leverages MultiCell's proprietary platform technologies in the science of modulating the human immune response to treat a range of serious diseases.
"We believe that this patent further validates our scientific and business model to develop drug candidates that work with the body's own immune system to deliver an entirely new generation of disease-specific immunotherapeutics," said Dr. Stephen Chang, President and Chief Executive Officer of MultiCell. "We have already advanced our products into human clinical trials where researchers have reported extremely encouraging results showing the efficacy of our drug candidates to treat patients with MS and other conditions that desperately need new and substantially better therapeutic options."
MultiCell is an innovator in the science of modulating the human immune system with unique platform technologies, focusing on the development of breakthrough drugs to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza. Currently, the market for therapies that address these diseases is estimated at $8 billion worldwide.
The newly issued patent is related to compositions for the effective endocytic presentation of immunosuppressive factors that are useful for the treatment of various disorders, such as autoimmune disorders. The Company's technology platforms include Toll-like Receptor signaling and T-cell targeting to modulate both the innate and adaptive immune systems. These technologies enable the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat MS-related chronic fatigue, relapsing-remitting multiple sclerosis, type-1 diabetes and infectious disease. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.MultiCelltech.com. For investor information about MultiCell, please visit http://www.trilogy-capital.com/tcp/multicell. For current stock price quotes and news, visit http://www.trilogy-capital.com/tcp/multicell/quote.html. To view the Company's Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/multicell/factsheet.html. To listen to an archived investor conference call, visit http://www.trilogy-capital.com/tcp/multicell/conference.html.
-------------------- Trading is a blast!! Posts: 4921 | From: Rhode Island | Registered: May 2005
| IP: Logged |
posted
i knew it i saw skips post hehe yeah sounds good, but im on the sidelines right now. gl matto!
Posts: 2794 | From: nyc | Registered: Aug 2005
| IP: Logged |
posted
ok juice i figured with the hints i gave poeple would figure it out! Understand that I would NEVER frontload or pump any stock,I am not a person who would hurt any traders- I teach and learn!!!
-------------------- Trading is a blast!! Posts: 4921 | From: Rhode Island | Registered: May 2005
| IP: Logged |
quote:Originally posted by matto: ok juice i figured with the hints i gave poeple would figure it out! Understand that I would NEVER frontload or pump any stock,I am not a person who would hurt any traders- I teach and learn!!!
2 good PRs came after-hours - MCET and HYPF; you did mention ACTC - easy to take one of two
by the way, no pre-market activity yet...
Posts: 1580 | From: World | Registered: Jul 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
![[Wink]](wink.gif)
yeah sounds good, but im on the sidelines right now. gl matto!
